PER 0.00% 7.8¢ percheron therapeutics limited

For General Information, page-1957

  1. 13,131 Posts.
    lightbulb Created with Sketch. 1374
    let me try to explain. Yu
    Anp re Atl1102 is for Non Ambulant boys with DMD( but could also work in Ambulant boys( Sarepta is only treating ambulant boys … but FDA want Sarepta to show data Re efficacy )

    Now Atl1102 shows potential to treat Limb girdle (R2)
    Sarepta does not have the Science (R2)
    So this is another market Anp could capture.

    Long Covid potential in discussion with interested parties;

    So each indication : Neuro muscular or Neuro Skeletal are yet to be defined.. in other words there are a many Rare Diseases that could be treated ( inflammation and fibrosis )

    Hope that helps
    We Wait $$




    Last edited by itsagas: 01/05/23
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.